United States · Platforms & data · MarketBeat

Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial

Published by MarketBeat · United States 31 min ago

Braveheart Bio (NASDAQ:BRVE) presented one-year data from a small study of its experimental heart drug BHB-1893 and outlined plans for a fixed-dose trial, as the company advances…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

The Motley Fool

Franklin (BEN) Q4 2026 Earnings Call Transcript

Seeking Alpha

Gogo reiterates $870M-$895M 2026 revenue guidance while outlining Galileo speeds to over 1 gigabit by 2032

Investing.com

Haiti PM says gang leader Mathias Saintil dead

MarketWatch

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

CNBC

Nasdaq drops into correction territory — here’s what typically happens next

Yahoo Finance